MX349886B - Moleculas de union anti-pseudomonas lectina pisum satinum (psl) y usos de las mismas. - Google Patents

Moleculas de union anti-pseudomonas lectina pisum satinum (psl) y usos de las mismas.

Info

Publication number
MX349886B
MX349886B MX2013014372A MX2013014372A MX349886B MX 349886 B MX349886 B MX 349886B MX 2013014372 A MX2013014372 A MX 2013014372A MX 2013014372 A MX2013014372 A MX 2013014372A MX 349886 B MX349886 B MX 349886B
Authority
MX
Mexico
Prior art keywords
binding molecules
psl binding
pseudomonas psl
pseudomonas
infection
Prior art date
Application number
MX2013014372A
Other languages
English (en)
Other versions
MX2013014372A (es
Inventor
Digiandomenico Antonio
G Warrener Paul
K Stover Charles
Sellman Bret
Tomich Mladen
Guillard Sandrine
Minter Ralph
Rust Steven
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of MX2013014372A publication Critical patent/MX2013014372A/es
Publication of MX349886B publication Critical patent/MX349886B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1214—Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a moléculas de unión anti-Ps1 de Pseudomonas y usos de las mismas, en particular en la prevención y el tratamiento de infección por Pseudomonas. Asimismo, la descripción proporciona composiciones y métodos para prevenir y tratar la infección por Pseudomonas.
MX2013014372A 2011-06-10 2012-06-08 Moleculas de union anti-pseudomonas lectina pisum satinum (psl) y usos de las mismas. MX349886B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161495460P 2011-06-10 2011-06-10
US201161530461P 2011-09-02 2011-09-02
US201261613317P 2012-03-20 2012-03-20
PCT/US2012/041538 WO2012170807A2 (en) 2011-06-10 2012-06-08 Anti-pseudomonas psl binding molecules and uses thereof

Publications (2)

Publication Number Publication Date
MX2013014372A MX2013014372A (es) 2014-08-21
MX349886B true MX349886B (es) 2017-08-17

Family

ID=47296761

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013014372A MX349886B (es) 2011-06-10 2012-06-08 Moleculas de union anti-pseudomonas lectina pisum satinum (psl) y usos de las mismas.

Country Status (23)

Country Link
US (4) US9403901B2 (es)
EP (2) EP2718320B1 (es)
JP (2) JP6058645B2 (es)
KR (1) KR102111171B1 (es)
CN (1) CN103974975B (es)
AU (3) AU2012267732A1 (es)
BR (1) BR112013031485B1 (es)
CA (1) CA2838211C (es)
CY (1) CY1120557T1 (es)
DK (1) DK2718320T3 (es)
ES (1) ES2664972T3 (es)
HK (1) HK1257190A1 (es)
HR (1) HRP20180458T1 (es)
HU (1) HUE038509T2 (es)
LT (1) LT2718320T (es)
MX (1) MX349886B (es)
PL (1) PL2718320T3 (es)
PT (1) PT2718320T (es)
RS (1) RS57024B1 (es)
RU (2) RU2014100111A (es)
SI (1) SI2718320T1 (es)
SM (1) SMT201800168T1 (es)
WO (1) WO2012170807A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2838211C (en) 2011-06-10 2023-08-01 Medimmmune Limited Anti-pseudomonas psl binding molecules and uses thereof
HUE050985T2 (hu) * 2011-11-07 2021-01-28 Medimmune Ltd Pseudomonas PSL és PCRV elleni kötõmolekulát alkalmazó kombinációs terápiák
KR20150082367A (ko) * 2012-11-06 2015-07-15 메디뮨 엘엘씨 항슈도모나스 ｐｓｌ 및 ｐｃｒｖ 결합 분자를 이용한 병용 요법
HK1223380A1 (zh) * 2013-05-14 2017-07-28 Medimmune, Llc 绿脓杆菌的psl外多糖的合成寡糖亚基
TWI805109B (zh) 2014-08-28 2023-06-11 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
GB201518668D0 (en) * 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
EP3383884A4 (en) 2015-11-30 2019-07-31 Medimmune Limited PROCESS FOR PREVENTING OR TREATING NOSOCOMIAL PNEUMONIA
KR20250011248A (ko) 2016-03-11 2025-01-21 스칼러 락, 인크. TGFβ1-결합 이뮤노글로불린 및 그의 용도
AU2017261374B2 (en) * 2016-05-05 2024-06-20 Inovio Pharmaceuticals, Inc. DNA antibody constructs for use against pseudomonas aeruginosa
WO2018186225A1 (ja) 2017-04-03 2018-10-11 富士フイルム株式会社 インク組成物及びその製造方法、並びに画像形成方法
GB201816554D0 (en) 2018-10-10 2018-11-28 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
GB201816553D0 (en) 2018-10-10 2018-11-28 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
US12459991B2 (en) 2019-02-12 2025-11-04 Regeneron Pharmaceuticals, Inc. Compositions and methods for using bispecific antibodies to bind complement and a target antigen
PE20221461A1 (es) * 2019-11-12 2022-09-21 Genzyme Corp Heteroarilaminosulfonamidas de 5 miembros para tratar afecciones mediadas por una actividad deficiente de cftr
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
CA3188725A1 (en) * 2020-08-07 2022-02-10 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing pseudomonas psl and uses thereof
WO2024123712A1 (en) * 2022-12-04 2024-06-13 Genentech, Inc. Analysis of candidate cytotoxic compositions
CN116059381B (zh) * 2022-12-29 2025-03-07 中国科学院长春应用化学研究所 一种兼具抗菌和抗炎作用的纳米颗粒及其制备方法和应用

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
WO1986005396A1 (fr) * 1985-03-11 1986-09-25 Teijin Limited ANTIGENE E87Ag DU PSEUDOMONAS AERUGINOSE, ANTICORPS MONOCLONAL CONTRE CET ANTIGENE ET HYBRIDOME
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE3668186D1 (de) 1985-04-01 1990-02-15 Celltech Ltd Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP1541682A3 (en) 1988-09-02 2005-07-06 Dyax Corp. Generation and selection of recombinant varied binding proteins
FI903489A0 (fi) 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
CA2110799A1 (en) 1991-06-14 1992-12-23 Arnold H. Horwitz Microbially-produced antibody fragments and their conjugates
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
DE69531148T2 (de) 1994-01-31 2004-04-29 Trustees Of Boston University, Boston Bibliotheken aus polyklonalen antikörpern
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6420140B1 (en) 1996-10-11 2002-07-16 Abgenix, Inc. Production of multimeric protein by cell fusion method
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
SI0970126T1 (en) 1997-04-14 2001-08-31 Micromet Ag Novel method for the production of antihuman antigen receptors and uses thereof
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
US6190370B1 (en) 1997-07-25 2001-02-20 Arrow International, Inc. Devices, systems and methods for determining proper placement of epidural catheters
DK1071752T3 (da) 1998-04-21 2003-10-20 Micromet Ag CD19xCD3-specifikke polypeptider og anvendelsen deraf
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
JP4368196B2 (ja) 2000-11-17 2009-11-18 ユニバーシティー オブ ロチェスター 真核細胞において免疫グロブリン分子を製造および同定するインビトロにおける方法
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
US20020146753A1 (en) 2001-04-06 2002-10-10 Henrik Ditzel Autoantibodies to glucose-6-phosphate isomerase and their participation in autoimmune disease
US7119172B2 (en) * 2001-05-21 2006-10-10 The Brigham And Women's Hospital, Inc. P. aeruginosa mucoid exopolysaccharide specific binding peptides
US20030232387A1 (en) 2002-06-14 2003-12-18 Millennium Pharmaceuticals, Inc. Antibodies that bind alphaE integrin
EP2500352A1 (en) 2005-08-19 2012-09-19 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20090215992A1 (en) 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
EP2044118A2 (en) 2006-06-13 2009-04-08 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
US7553936B2 (en) 2006-12-04 2009-06-30 The United States of America as represented by Secretary Department of Health and Human Services Anti-TREM-like transcript-1 (TLT-1) antibodies and compositions
AU2007336243B2 (en) 2006-12-19 2012-07-26 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
CA2706732A1 (en) * 2007-11-30 2009-06-11 Kalobios Pharmaceuticals, Inc. Antibodies to the pcrv antigen of pseudomonas aeruginosa
WO2009088032A1 (ja) 2008-01-10 2009-07-16 Shionogi & Co., Ltd. ＰｃｒＶに対する抗体
BRPI0907046A2 (pt) 2008-01-18 2015-07-28 Medimmune Llc Anticorpo de cisteína engenheirada, ácido nucleico isolado, vetor, célula hospedeira, conjugado de anticorpo, composição farmacêutica, métodos de detecção de câncer, doenças ou distúrbios autoimunes, inflamatórios ou infecciosos em um indivíduo e de inibição de proliferação de uma célula alvo
AU2009319856A1 (en) 2008-11-28 2010-06-03 Abbvie Inc. Stable antibody compositions and methods for stabilizing same
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
CA2751433A1 (en) 2009-02-04 2010-08-12 Kalobios Pharmaceuticals, Inc. Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection
EP2408475B1 (en) 2009-03-18 2017-11-15 Wake Forest University Health Sciences Flagellin fusion proteins and use thereof to induce immune responses against pseudomonas aeruginosa
WO2010108154A2 (en) 2009-03-20 2010-09-23 Amgen Inc. Selective and potent peptide inhibitors of kv1.3
JP2012523221A (ja) * 2009-04-09 2012-10-04 ケンタ バイオテク アーゲー 緑膿菌（Ｐｓｅｕｄｏｍｏｎａｓａｅｒｕｇｉｎｏｓａ）のＩＡＴＳＯ１血清型のリポ多糖類（ＬＰＳ）に対して特異的なヒトモノクローナル抗体
WO2011005481A1 (en) 2009-06-22 2011-01-13 Medimmune, Llc ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
JP2013515079A (ja) 2009-12-22 2013-05-02 カロバイオス ファーマシューティカルズ インコーポレイティッド 低レベルの病原性シュードモナス・エルギノーサ（Ｐｓｅｕｄｏｍｏｎａｓａｅｒｕｇｉｎｏｓａ）感染症を有する患者のスタフィロコッカス（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ）感染症を治療する方法
SG10201913690SA (en) 2011-02-08 2020-03-30 Medimmune Llc Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
CA2838211C (en) 2011-06-10 2023-08-01 Medimmmune Limited Anti-pseudomonas psl binding molecules and uses thereof
EP2776061B1 (en) 2011-11-07 2019-08-14 MedImmune, LLC Multispecific and multivalent binding proteins and uses thereof
HUE050985T2 (hu) * 2011-11-07 2021-01-28 Medimmune Ltd Pseudomonas PSL és PCRV elleni kötõmolekulát alkalmazó kombinációs terápiák
KR20150082367A (ko) 2012-11-06 2015-07-15 메디뮨 엘엘씨 항슈도모나스 ｐｓｌ 및 ｐｃｒｖ 결합 분자를 이용한 병용 요법
KR20150092738A (ko) 2012-11-06 2015-08-13 메디뮨 엘엘씨 에스.아우레우스 연관 질병의 치료 방법
CN104968797B (zh) 2012-11-06 2018-11-30 米迪缪尼有限公司 金黄色葡萄球菌表面决定簇的抗体
HK1223380A1 (zh) * 2013-05-14 2017-07-28 Medimmune, Llc 绿脓杆菌的psl外多糖的合成寡糖亚基
US20170183397A1 (en) 2014-05-05 2017-06-29 Medimmune, Llc Multi-specific anti-pseudomonas psl and pcrv binding molecules and uses thereof
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
EP3383884A4 (en) 2015-11-30 2019-07-31 Medimmune Limited PROCESS FOR PREVENTING OR TREATING NOSOCOMIAL PNEUMONIA
AU2017261374B2 (en) 2016-05-05 2024-06-20 Inovio Pharmaceuticals, Inc. DNA antibody constructs for use against pseudomonas aeruginosa
JP6988094B2 (ja) 2017-01-27 2022-01-05 富士フイルムビジネスイノベーション株式会社 ポリイミド前駆体組成物、及びポリイミド成形体の製造方法

Also Published As

Publication number Publication date
RS57024B1 (sr) 2018-05-31
ES2664972T3 (es) 2018-04-24
KR20140034877A (ko) 2014-03-20
US20210130442A1 (en) 2021-05-06
JP6420813B2 (ja) 2018-11-07
BR112013031485B1 (pt) 2022-06-14
WO2012170807A2 (en) 2012-12-13
EP2718320A2 (en) 2014-04-16
CA2838211A1 (en) 2012-12-13
AU2012267732A1 (en) 2014-01-09
RU2018102606A3 (es) 2019-02-22
US20160297872A1 (en) 2016-10-13
JP2014519334A (ja) 2014-08-14
HRP20180458T1 (hr) 2018-06-29
US10844114B2 (en) 2020-11-24
LT2718320T (lt) 2018-04-10
EP2718320A4 (en) 2015-03-04
AU2017204447A1 (en) 2017-07-20
AU2019257355A1 (en) 2019-11-14
AU2017204447B2 (en) 2019-08-01
CN103974975A (zh) 2014-08-06
RU2708977C2 (ru) 2019-12-12
JP6058645B2 (ja) 2017-01-11
PL2718320T3 (pl) 2018-06-29
SI2718320T1 (en) 2018-06-29
HUE038509T2 (hu) 2018-10-29
EP3385280A1 (en) 2018-10-10
WO2012170807A3 (en) 2013-03-28
RU2014100111A (ru) 2015-07-20
BR112013031485A2 (pt) 2016-11-22
CY1120557T1 (el) 2019-07-10
PT2718320T (pt) 2018-03-26
NZ618266A (en) 2016-04-29
US20190322726A1 (en) 2019-10-24
KR102111171B1 (ko) 2020-05-14
MX2013014372A (es) 2014-08-21
RU2018102606A (ru) 2019-02-22
BR112013031485A8 (pt) 2022-05-17
HK1257190A1 (en) 2019-10-18
CN103974975B (zh) 2018-06-29
US20140227285A1 (en) 2014-08-14
US9403901B2 (en) 2016-08-02
CA2838211C (en) 2023-08-01
JP2017074057A (ja) 2017-04-20
DK2718320T3 (en) 2018-03-26
SMT201800168T1 (it) 2018-05-02
EP2718320B1 (en) 2018-01-10
US10370436B2 (en) 2019-08-06

Similar Documents

Publication Publication Date Title
MX349886B (es) Moleculas de union anti-pseudomonas lectina pisum satinum (psl) y usos de las mismas.
WO2013070615A8 (en) Combination therapies using anti- pseudomonas psl and pcrv binding molecules
EA201291031A1 (ru) Способ лечения ожирения с применением антиоксидантных модуляторов воспаления
MX2013012165A (es) Composicion y metodo para mejorar una respuesta inmune.
IN2012DN03883A (es)
EP2569434A4 (en) COMPOSITIONS AND METHODS OF TREATING LEUKEMIA
MX2015007556A (es) Derivados de manosa para tratar infecciones bacterianas.
MX2013008547A (es) Composicion efervescente en forma solida para uso en aplicaciones vaginales para el tratamiento de infecciones vaginales.
PH12012501841B1 (en) Anti-infective compounds
HK1220980A1 (zh) 用於治疗庞贝氏症的方法和组合物
PH12017500864A1 (en) Anti-notch1 antibodies
PH12014500904B1 (en) Antibody formulations and methods
PH12014500075A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MX372858B (es) Sistemas y métodos de tratamiento de agua.
WO2011129936A3 (en) Compositions and methods for the prevention and treatment of cancer
MX2012013875A (es) Anticuerpos de union sparc en sangre periferica y usos de los mismos.
IN2014DN08385A (es)
WO2013037943A8 (en) Compositions and methods for treating cancer using pi3k beta inhibitor and mapk pathway inhibitor, including mek and raf inhibitors
WO2012017321A3 (en) Treatment for dyslipidemia
WO2013106460A3 (en) Compositions and methods for treating malignant astrocytomas
UA115305C2 (uk) Композиції hyr1-похідних і способи лікування ними
IN2014DN00254A (es)
EP2597949A4 (en) SUBMIKROMETERZUSAMMENSETZUNGEN
WO2012024670A3 (en) Composition and methods for treating glioblastoma
WO2011019636A3 (en) Methods and compositions for the treatment of cancers and pathogenic infections

Legal Events

Date Code Title Description
FG Grant or registration